tbuckley/cabot-search huggingface dataset:
BMA annual representative meeting, Torquay: Doctors postpone decision on industrial action
Authors: Annabel Ferriman
Journal: BMJ (2003)

Doctors at the annual representative meeting of the BMA this week decided not to endorse earlier calls for a ballot on industrial action from the annual consultants' conference in the light of an imminent meeting with the new health secretary, Dr John Reid. Consultant leaders were due to meet Dr Reid on 4 July.

They passed a motion regretting the impasses in delivering a new consultant contract to deliver a modern, patient focused service while improving consultant working lives, and welcoming the commitment by the new secretary of state for health.

The motion also recognised what it described as the “justified” anger of the consultant body and supported the Central Consultants and Specialists Committee in requesting whatever action it considered necessary, including industrial action, should talks fail.

Dr Paul Miller, chairman of the consultants' committee, said that the consultants had been accused of being both the forces of conservatism and militants, threatening industrial action. But in fact, he said, they had always been the modernisers, the reformers of patient services, as well as representing the independent professional view in the NHS and being the advocates of patients.

“Now, at last, our new secretary of state has arranged to meet us on Friday, and says he wants to sort it out, to work with us to address the problems. I welcome that, and he will find us prepared and keen to work hard with him.

“It is easy, so easy, to find grounds for disagreement, and we have the stomach for the fight, if necessary. It is much harder to find agreements. But we stand ready to do the hard thing, to put the conflict behind us, to achieve a new contract which will be good for patients and good for consultants.”

Dr Ian Wilson, a consultant anaesthetist from Dewsbury, warned Dr Reid that he should not mistake “our willingness to work with you as a sign of weakness.”

He added that if Dr Reid tried to undermine doctors' professionalism and their ability to look after their patients, by “a Stalinist, centralist, control freak agenda, you will see the mettle of which we are made.”
Case 5-1965
Authors: John H. Knowles, Benjamin Castleman
Journal: New England Journal of Medicine (1965)

Presentation of Case First admission. A fifty-three-year-old woman was admitted to the hospital because of a chronic nasal discharge.She had been well until one year previously, when she began to have a brownish discharge from the left nostril, accompanied by occasional epistaxis and numbness of the left side of the face. There was a history of rheumatic fever in childhood.Physical examination revealed a woman who appeared well. Examination of the nose disclosed a polypoid, friable lesion in the left nasal cavity. The lungs were clear. The heart was not enlarged; a Grade 2 basal systolic murmur was . . .
Managing Children with Psychiatric Problems
Authors: D Black
Journal: BMJ (1994)

Children with problems of behaviour and emotions are the bread and butter of paediatric practice and are common in general practice, making up over a third of all consultations. General practitioners get little training in how to manage such children and their families, and paediatric training is patchy. Managing Children with Psychiatric Problems is an authoritative and comprehensive account of the main treatments used by child and adolescent psychiatry departments that is designed to help general practitioners, paediatricians, and social workers find a way of dealing more effectively with troubled or troubling children and …
The Sick Child
Authors: M Therese Southgate
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reverse Transcription Errors and RNA–DNA Differences at Short Tandem Repeats
Authors: Arkarachai Fungtammasan, Marta Tomaszkiewicz, Rebeca Campos-Sánchez, Kristin A. Eckert, Michael DeGiorgio, Kateryna D. Makova
Journal: Molecular Biology and Evolution (2016)

Transcript variation has important implications for organismal function in health and disease. Most transcriptome studies focus on assessing variation in gene expression levels and isoform representation. Variation at the level of transcript sequence is caused by RNA editing and transcription errors, and leads to nongenetically encoded transcript variants, or RNA–DNA differences (RDDs). Such variation has been understudied, in part because its detection is obscured by reverse transcription (RT) and sequencing errors. It has only been evaluated for intertranscript base substitution differences. Here, we investigated transcript sequence variation for short tandem repeats (STRs). We developed the first maximum-likelihood estimator (MLE) to infer RT error and RDD rates, taking next generation sequencing error rates into account. Using the MLE, we empirically evaluated RT error and RDD rates for STRs in a large-scale DNA and RNA replicated sequencing experiment conducted in a primate species. The RT error rates increased exponentially with STR length and were biased toward expansions. The RDD rates were approximately 1 order of magnitude lower than the RT error rates. The RT error rates estimated with the MLE from a primate data set were concordant with those estimated with an independent method, barcoded RNA sequencing, from a Caenorhabditis elegans data set. Our results have important implications for medical genomics, as STR allelic variation is associated with >40 diseases. STR nonallelic transcript variation can also contribute to disease phenotype. The MLE and empirical rates presented here can be used to evaluate the probability of disease-associated transcripts arising due to RDD.
Soundings: Pedalling up the Amazon
Authors: James Owen Drife
Journal: BMJ (2004)

I have been subscribing to a local fitness centre for years but have not lost any weight at all. Sometimes my wife suggests that I ought to go and at least look at the place. She says it is delightful, full of slim people of both genders.

That's the trouble. What I want to kick-start my personal struggle against cuddliness is a gymnasium where I don't stick out. I resemble the “before” part of the advertisements and I feel conspicuous. More muscle would be nice, certainly, but what I really need is nerve.

My opportunity came on our last cruise. Like most people these days we take a winter holiday but we are non-skiers. This year, South America was as far off-piste as we could get.

The routine history at booking, at least with this cruise company, is: “Are you a wheelchair user?” No. “Will you be bringing your own oxygen?” No. “Do you require syringes and needles?” Certainly not. By the time you put the phone down you feel years younger.

On board, the fitness centre was on deck 9 at the front—near the internet cafe. My wife radiated silent approval of my trips for'ard until, two days out from Recife, she caught me among the workaholics logging in to the office email.

Shortly afterwards I was in the gym, blending in with other first timers as Katie, the youthful instructor, explained which piece of apparatus trains what. She related well to wrinklies. She made jokes, avoided looking at our bodies, and knew about cardiopulmonary resuscitation. It was my kind of place, I decided.

Pedalling against resistance with a pulse rate of 120, I waited for the endorphin surge. Katie had said you had to break sweat.

The last time I was in a gym, back in 1964, it was all wallbars, ropes, and beams. Now I had a digital display of calories burned and a button to press if I needed to go downhill.

Time to pump some iron. Adjust the peg to reduce the weight. The last user must have been some kind of a freak. Outside, the banks of the Amazon slid past. Inside, I was doing 3.6 mph on the running track.

Feel the burn, man. Get some samba CDs for the Walkman and this just might change your life.
Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity
Authors: Jannick Prentoe, Rodrigo Velázquez‐Moctezuma, Steven K.H. Foung, Mansun Law, Jens Bukh
Journal: Hepatology (2016)

There are 3‐4 million new hepatitis C virus (HCV) infections yearly. The extensive intergenotypic sequence diversity of envelope proteins E1 and E2 of HCV and shielding of important epitopes by hypervariable region 1 (HVR1) of E2 are believed to be major hindrances to developing universally protective HCV vaccines. Using cultured viruses expressing the E1/E2 complex of isolates H77 (genotype 1a), J6 (2a), or S52 (3a), with and without HVR1, we tested HVR1‐mediated neutralization occlusion in vitro against a panel of 12 well‐characterized human monoclonal antibodies (HMAbs) targeting diverse E1, E2, and E1/E2 epitopes. Surprisingly, HVR1‐mediated protection was greatest for S52, followed by J6 and then H77. HCV pulldown experiments showed that this phenomenon was caused by epitope shielding. Moreover, by regression analysis of HMAb binding and neutralization titer of HCV we found a strong correlation for HVR1‐deleted viruses but not for parental viruses retaining HVR1. The intergenotype neutralization sensitivity of the parental viruses to HMAb antigenic region (AR) 2A, AR3A, AR4A, AR5A, HC84.26, and HC33.4 varied greatly (&gt;24‐fold to &gt;130‐fold differences in 50% inhibitory concentration values). However, except for AR5A, these differences decreased to less than 6.0‐fold when comparing the corresponding HVR1‐deleted viruses. Importantly, this simplified pattern of neutralization sensitivity in the absence of HVR1 was also demonstrated in a panel of HVR1‐deleted viruses of genotypes 1a, 2a, 2b, 3a, 5a, and 6a, although for all HMAbs, except AR4A, an outlier was observed. Finally, unique amino acid residues in HCV E2 could explain these outliers in the tested cases of AR5A and HC84.26. Conclusion: HVR1 adds complexity to HCV neutralization by shielding a diverse array of unexpectedly cross‐genotype‐conserved E1/E2 epitopes. Thus, an HVR1‐deleted antigen could be a better HCV vaccine immunogen. (H epatology 2016;64:1881‐1892)
DNA Damage Induced by DNA Topoisomerase I- and Topoisomerase II- Inhibitors Detected by Histone H2AX Phosphorylation in Leukemic Cells.
Authors: Dorota H. Halicka, Xuan Huang, Fevzi M. Ozkaynak, Karen Seiter, Frank Traganos, Zbigniew Darzynkiewicz
Journal: Blood (2004)
On the Road to Better National Surgical Data in Low-Income and Middle-Income Countries
Authors: Andrew J. M. Leather, Anna J. Dare
Journal: JAMA Surgery (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
P-174 Ramucirumab and paclitaxel in platin refractory advanced or metastatic gastric or gastrooesophageal junction adenocarcinoma – a single center experience
Authors: U. Vogl, L. Vormittag, T. Winkler, A. Kafka, O. Weiser-Jasch, H. Andalibi, W. Schima, A. Klaus, J. Zacherl, L. Öhler
Journal: Annals of Oncology (2016)
Mirage
Authors: Janet M. Torpy
Journal: JAMA (2012)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Systemic treatment with anti-PD-1 antibody nivolumab in combination with vaccine therapy in advanced pancreatic cancer.
Authors: Jan Nesselhut, Dagmar Marx, Hans Lange, Goncalo Regalo, Nicole Cillien, Raymond Y. Chang, Thomas Nesselhut
Journal: Journal of Clinical Oncology (2016)

3092 Background: Systemic treatment with antibodies against PD-1 has shown promising results in many solid tumors with pancreatic cancer being one of the few exceptions. This may be due to failure of activation and/or recruitment of effector T cells into the tumor. An effective immune response against tumors requires the inhibition of inhibitory signals as well as the activation of antigen specific T-cell response. Thus, therapy efficacy may be improved by combination of anti-PD-1 therapy and dendritic cell vaccines. Methods: Seven patients with stage IV pancreatic cancer included in this pilot study received a treatment with nivolumab and dendritic cells (DC). After isolating monocytes from peripheral blood of the patients, antigen primed MoDC were generated using standard protocols. Nivolumab was given one day before the DC vaccine at a reduced dose of 1-2 mg/kg body weight. Cytokine release of DC and T-cell activity in relation to nivolumab therapy were measured using a standard mixed lymphocyte culture (MLC). Results: Using Recist criteria we observed 2 partial remissions with overall survival after onset of therapy of 13 months and 5 months respectively (at time of abstract submission). Both patients are still alive with an ongoing therapy response. Most patients tolerate the therapy well with only mild side effects upon nivolumab therapy. Cytokine measurement using MLC, showed a change in the cytokine release when nivolumab was added to the culture. Conclusions: At ASCO 2015 we demonstrated that the efficacy of DC based therapy can be improved by blockade of PD-L1 on dendritic cells improving the T-cell specific response. Here we show that systemic anti-PD-1 therapy for patients with pancreatic cancer can be effective even at lower dose when combined with DC vaccine therapy.
LSC 2011 Abstract: T helper 17 cell involvement in COPD and lung transplantation patients
Authors: Marthe Paats, Ingrid Bergen, Menno van der Eerden, Bernt van den Blink, Peter van Hal, Nicole van Besouw, Carla Baan, Henk Hoogsteden, Rudi Hendriks
Journal: European Respiratory Journal (2011)

Background:  COPD is associated with airway and systemic inflammation and end stage disease is a major indication for lung transplantation (LTx). The novel T helper 17 (Th17) subset was recently implicated in the pathogenesis of COPD and is also associated with allograft rejection. To date, little is known about the cytokine profile of circulating T cells in COPD and LTx patients.   Aim:  To determine the cytokine profile of circulating T cells in patients with COPD and in stable LTx patients.   Methods:  Peripheral blood mononuclear cells of COPD patients, before and 1 year after LTx and of healthy controls were shortly stimulated  in vitro  and T cells were analysed by flow cytometry for intracellular cytokine production.   Results:  We found no differences in proportions of Th17 cytokines (IL17A, IL22, IL17F) in stable COPD patients when compared to healthy controls. In the LTx patients, proportions of IFNγ and TNFα producing T cells did not differ from those in healthy controls. However, IL22 production by CD4 +  and CD8 +  T cells was increased in LTx patients. Also, an increase in the proportions of IL17 + IL22 +  and IL17 + IFNγ +  double positive T cells was found in stable LTx patients when compared with healthy controls.   Conclusions:  Remarkably, T cells of LTx patients have the capacity to produce high levels of proinflammatory cytokines despite immunosuppressive drug treatment. In particular, IL22 +  T cells and specific populations of IL17 +  cells co-expressing IL22 or IFNγ are high in LTx patients, while IFNγ and TNFα single positive T helper cells are not increased. These findings indicate that there is no general systemic inflammatory state but that specific Th17-linked subpopulations may play a role in stable LTx patients.
Low-Dose Fludarabine and Cyclophosphamide Combined with Rituximab In the Treatment of Elderly/Comorbid Patients with chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Preliminary Results of Project Q-Lite by Czech CLL Study Group
Authors: Lukas Smolej, Martin Spacek, Yvona Brychtova, David Belada, Jiri Schwarz, Michael Doubek, Monika Motyckova, Eduard Cmunt, Peter Rohon, Katerina Klaskova, Tomas Kozak
Journal: Blood (2010)
Abstract P4-14-05: Skin sparing mastectomy – thorough breast tissue removal leads to a low local recurrence rate of breast cancer
Authors: AJ Paily, EH Drabble
Journal: Cancer Research (2012)

Abstract Introduction: Skin sparing mastectomy (SSM) has the dual advantage of being an acceptable treatment for breast cancer as well as preserving a skin envelope for better aesthesis and cosmesis. However, SSM and immediate breast reconstruction for early breast cancer is not based on level-1 evidence. Even though oncological recurrence is equivalent to that with skin removing mastectomies, most studies have only short term follow-ups. Local Recurrence (LR) or the threat of it is becoming an increasing issue for us as 1 in 4 will succumb from local recurrence. We present local recurrence (LR) and systemic recurrence (SR) rates and the aesthetic results following SSM with or without immediate reconstruction. Methods and materials: Over a period of 10 years, 249 patients undergoing SSM with or without immediate reconstruction were identified from a prospectively recorded database and complete details of all their treatments and outcomes were assessed. The reconstructive methods employed included Transverse Rectus Abdominus Myocutaneous (TRAM) flap, Latissimus Dorsi (LD) flap in isolation or along with an implant and subpectoral implant insertion. LR and SR rates were determined. Pathological examination of biopsies from the skin flaps after SSM, were also analysed. Results: Of the 249 patients who underwent SSM, only 34 did not have immediate breast reconstruction. The overall LR and SR rates were 0.4% and 4.4% respectively. 76 patients underwent SSM and TRAM flap reconstruction (1 LR and 5 SR). 33 patients had LD flap reconstruction (no LR and 1 SR). 61 patients were given LD flap reconstruction with implants (no LR and 4 SR). SSM and insertion of sub-pectoral implants was performed on 45 patients (no LR and no SR). 34 patients underwent SSM without immediate reconstruction (no LR, 1 SR). All 249 patients had no evidence of residual breast tissue in subcutaneous flap biopsies. Of the 215 patients who underwent immediate reconstruction, 140 had a good aesthetic result (65%). Individually, TRAM flap and LD flap with implant insertion each produced the best aesthetic result (74%). While reconstructions with LD flaps alone did result in a good aesthetic result in 70% of patients, it also had the poorest aesthetic result (12%) compared to the other three groups. Conclusion: SSM with or without immediate breast reconstruction performed in our unit has shown a very low rate of LR compared to that in literature. In addition, flap biopsies have shown no residual breast tissue in our patients highlighting that thorough removal of breast tissue at skin sparing mastectomy leads to low LR rates. Our systemic recurrence rates are much higher than local recurrence rates, but are still as expected or slightly lower than expected. Our approach therefore achieves thorough removal of breast tissue and we believe that this leads to a low local recurrence rate, but with good aesthetic results. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P4-14-05.
Pharmacokinetics of H002, a novel S1PR1 modulator, and its metabolites in rat blood using liquid chromatography–tandem mass spectrometry
Authors: Jiaqi Mi, Manman Zhao, Shu Yang, Shuang Yang, Jing Jin, Xiaojian Wang, Qiong Xiao, Jinping Hu, Yan Li
Journal: Acta Pharmaceutica Sinica B (2016)

A rapid and sensitive liquid chromatography–tandem mass spectrometry (LC–MS/MS) method was developed and validated for the simultaneous determination of H002 and its phosphorylated metabolite, H002-P and hydroxylated metabolite H002-M, in rat blood. H001, an analogue of H002, was used as the internal standard. Blood samples were prepared by simple protein precipitation. The analytes and internal standard were separated on a Zorbax SB-C18 column with a gradient mobile phase consisting of methanol and water containing 0.1% formic acid at a flow rate of 0.2 mL/min with an operating temperature of 20 °C. The detection was performed on a triple quadrupole tandem mass spectrometer with positive electrospray ionization in multiple-reaction monitoring mode. Linear detection responses were obtained from 0.2–100 ng/mL for H002 and H002-M, while 0.5–100 ng/mL for H002-P. The intra- and inter-day precision (RSD%) was within 11.76%, with the accuracy (RE%) ranging from –9.84% to 9.12%. The analytes were shown to be stable during sample storage, preparation and analytic procedures. The method was applied to determine the pharmacokinetics of H002 in rats, and a preliminary study showed that the pharmacokinetics of H002 correlated with its biological effect on peripheral blood lymphocytes.
Anoxia and glucose supplementation preserve neutrophil viability and function
Authors: Valérie Monceaux, Clarisse Chiche-Lapierre, Catherine Chaput, Véronique Witko-Sarsat, Marie-Christine Prevost, Cormac T. Taylor, Marie-Noelle Ungeheuer, Philippe J. Sansonetti, Benoit S. Marteyn
Journal: Blood (2016)